-
Product Insights
Glioblastoma Multiforme (GBM): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Glioblastoma Multiforme (GBM) - Global Clinical Trials Review, 2026" provides an overview of Glioblastoma Multiforme (GBM) Clinical trials scenario. This report provides top line data relating to the clinical trials on Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Recurrent Glioblastoma Multiforme (GBM) - Drugs In Development, 2024
Empower your strategies with our Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent glioblastoma multiforme (GBM) refers to the return of aggressive brain tumors known as glioblastomas after initial treatment. GBM is the most malignant type of glioma, characterized by rapid growth and infiltrative behavior. Despite aggressive therapies like surgery, radiation, and chemotherapy, GBM often recurs due to its invasive nature and resistance to treatment. Management of recurrent GBM poses significant challenges....
-
Sector Analysis
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Report Overview In 2023, the highest incident cases of Glioblastoma Multiforme (GBM) were from China and India. Glioblastoma Multiforme is a fast-growing and aggressive brain tumor. It is also referred to as a grade IV astrocytoma. GBM invades the nearby brain tissue but generally does not spread to distant organs. There are only a handful of innovator treatment options approved for the treatment of GBM and most conventional marketed drugs are small molecules,...
-
Sector Analysis
Glioblastoma Multiforme (GBM) - Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional GBM therapies was $630 million in 2021. High usage of dendritic cell vaccines and oncolytic viruses that demonstrate significant survival advantages will drive market growth during the forecast period. Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Glioblastoma Multiforme (GBM) – Cell...
-
Sector Analysis
Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030
Glioblastoma multiforme (GBM) is now defined by the WHO 2021 as a diffuse astrocytic glioma with no mutations in IDH genes or histone H3 genes. It is the most common primary brain tumor in humans. Like other astrocytomas, GBM originates from astrocytes, a type of glial cells that are non-neuronal and function to provide structural and biochemical support to the brain's neuronal network. GBM continues to be a disease with some of the highest unmet needs in oncology, with patients...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.